Spyre Therapeutics (SYRE.US) was first covered by Baird, which gave it an superior market rating and a target price of $50.00.
Spyre Therapeutics(SYRE.US)获Baird首次覆盖，给予优于大市评级, 目标价50.00美元。
Spyre Therapeutics (SYRE.US) was first covered by Baird, which gave it an superior market rating and a target price of $50.00.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.